Northwest Biotherapeutics (NWBO) Income from Continuing Operations: 2010-2025
Historic Income from Continuing Operations for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$16.9 million.
- Northwest Biotherapeutics' Income from Continuing Operations fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' Income from Continuing Operations stood at -$16.9 million, which was down 2.02% from -$16.6 million recorded in Q2 2025.
- Northwest Biotherapeutics' Income from Continuing Operations' 5-year high stood at -$11.7 million during Q3 2021, with a 5-year trough of -$22.5 million in Q2 2022.
- In the last 3 years, Northwest Biotherapeutics' Income from Continuing Operations had a median value of -$16.9 million in 2024 and averaged -$17.0 million.
- Data for Northwest Biotherapeutics' Income from Continuing Operations shows a peak YoY increase of 78.18% (in 2021) and a maximum YoY decrease of 148.49% (in 2021) over the last 5 years.
- Northwest Biotherapeutics' Income from Continuing Operations (Quarterly) stood at -$11.8 million in 2021, then slumped by 64.00% to -$19.4 million in 2022, then climbed by 15.54% to -$16.4 million in 2023, then fell by 28.09% to -$21.0 million in 2024, then dropped by 0.36% to -$16.9 million in 2025.
- Its Income from Continuing Operations was -$16.9 million in Q3 2025, compared to -$16.6 million in Q2 2025 and -$18.9 million in Q1 2025.